FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3159508826> ?p ?o ?g. }

• W3159508826 abstract "Objective: To report the case of a 35-year-old woman with treatment-resistant aquaporin-4 (AQP-4) immunoglobulin G (IgG) seronegative neuromyelitis optica spectrum disorder (NMOSD) successfully treated with eculizumab (a terminal complement inhibitor). Methods: The investigational procedures and treatment regimens the patient received were documented over 8 years [2012 (first presentation) to 2020]. Results: The patient presented with subacute onset of lower-limb weakness and numbness, gait imbalance, and urinary incontinence. Magnetic resonance imaging (MRI) showed abnormalities in the thoracic spine from T7 to T10, but brain and cervical spine scans, visual evoked potential latencies, and IgG index were normal; cerebrospinal fluid pleocytosis and oligoclonal bands were both present. After treatment with intravenous methylprednisolone 1 g/day for 5 days, the patient was discharged without medication to acute rehabilitation but experienced relapses from 2012 to 2014. She was treated with oral prednisone (initiated at 40 mg/day in 2014; the dose was halved in 2015 due to weight gain) and mycophenolate mofetil (MMF) 1 g twice daily (from June 2015), but between 2014 and 2019 experienced 4–5 relapses/year, requiring treatment with intravenous methylprednisolone, with added maintenance plasma exchange from 2018 onwards. Although the patient tested negative for antibodies to AQP-4 and myelin oligodendrocyte glycoprotein, she was diagnosed with NMOSD in February 2017, based on recurrent episodes of longitudinal extensive transverse myelitis, MRI changes, and area postrema syndrome. By 2018 the patient needed a cane to walk. Prednisone and MMF were discontinued mid-2018, and rituximab was prescribed from July 2018 (maintenance regimen two 1 g doses 2 weeks apart every 6 months) but discontinued in July 2019 owing to lack of significant improvement. From July 2019 eculizumab was prescribed for 6 months (900 mg weekly for the first four doses, then 1200 mg every 2 weeks). The patient had no relapses or adverse events during and after eculizumab treatment (as of August 2020) and was able to walk unaided; her Expanded Disability Status Scale score improved from 4–5 during 2015–2018 to 2 in 2020 following eculizumab treatment. Conclusion: Eculizumab shows promise as a treatment for AQP-4 IgG-seronegative NMOSD and further studies are warranted." @default.
• W3159508826 created "2021-05-10" @default.
• W3159508826 creator A5035925457 @default.
• W3159508826 creator A5068289916 @default.
• W3159508826 creator A5074497689 @default.
• W3159508826 creator A5081440049 @default.
• W3159508826 date "2021-05-06" @default.
• W3159508826 modified "2023-10-18" @default.
• W3159508826 title "Eculizumab in the Treatment of Aquaporin-4 Seronegative Neuromyelitis Optica Spectrum Disorder: A Case Report" @default.
• W3159508826 cites W1970614998 @default.
• W3159508826 cites W1998908782 @default.
• W3159508826 cites W2027269546 @default.
• W3159508826 cites W2094929674 @default.
• W3159508826 cites W2114414511 @default.
• W3159508826 cites W2129229339 @default.
• W3159508826 cites W2142933810 @default.
• W3159508826 cites W2144469764 @default.
• W3159508826 cites W2208791667 @default.
• W3159508826 cites W2290972543 @default.
• W3159508826 cites W2399721277 @default.
• W3159508826 cites W2524675862 @default.
• W3159508826 cites W2747647717 @default.
• W3159508826 cites W2911053528 @default.
• W3159508826 cites W2933712812 @default.
• W3159508826 cites W2943416206 @default.
• W3159508826 cites W2971906807 @default.
• W3159508826 cites W3012054652 @default.
• W3159508826 cites W3037214622 @default.
• W3159508826 cites W3088822708 @default.
• W3159508826 cites W3111003275 @default.
• W3159508826 doi "https://doi.org/10.3389/fneur.2021.660741" @default.
• W3159508826 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8134535" @default.
• W3159508826 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34025563" @default.
• W3159508826 hasPublicationYear "2021" @default.
• W3159508826 type Work @default.
• W3159508826 sameAs 3159508826 @default.
• W3159508826 citedByCount "3" @default.
• W3159508826 countsByYear W31595088262021 @default.
• W3159508826 countsByYear W31595088262022 @default.
• W3159508826 countsByYear W31595088262023 @default.
• W3159508826 crossrefType "journal-article" @default.
• W3159508826 hasAuthorship W3159508826A5035925457 @default.
• W3159508826 hasAuthorship W3159508826A5068289916 @default.
• W3159508826 hasAuthorship W3159508826A5074497689 @default.
• W3159508826 hasAuthorship W3159508826A5081440049 @default.
• W3159508826 hasBestOaLocation W31595088261 @default.
• W3159508826 hasConcept C111684460 @default.
• W3159508826 hasConcept C118552586 @default.
• W3159508826 hasConcept C126322002 @default.
• W3159508826 hasConcept C141071460 @default.
• W3159508826 hasConcept C159654299 @default.
• W3159508826 hasConcept C187212893 @default.
• W3159508826 hasConcept C203014093 @default.
• W3159508826 hasConcept C2522874641 @default.
• W3159508826 hasConcept C2776572573 @default.
• W3159508826 hasConcept C2777185649 @default.
• W3159508826 hasConcept C2777483564 @default.
• W3159508826 hasConcept C2777604421 @default.
• W3159508826 hasConcept C2777704947 @default.
• W3159508826 hasConcept C2777991916 @default.
• W3159508826 hasConcept C2778720950 @default.
• W3159508826 hasConcept C2779338263 @default.
• W3159508826 hasConcept C2779651940 @default.
• W3159508826 hasConcept C2780372218 @default.
• W3159508826 hasConcept C2780636500 @default.
• W3159508826 hasConcept C2780640218 @default.
• W3159508826 hasConcept C2780653079 @default.
• W3159508826 hasConcept C2780775167 @default.
• W3159508826 hasConcept C2781137167 @default.
• W3159508826 hasConcept C71924100 @default.
• W3159508826 hasConcept C83455156 @default.
• W3159508826 hasConcept C90924648 @default.
• W3159508826 hasConceptScore W3159508826C111684460 @default.
• W3159508826 hasConceptScore W3159508826C118552586 @default.
• W3159508826 hasConceptScore W3159508826C126322002 @default.
• W3159508826 hasConceptScore W3159508826C141071460 @default.
• W3159508826 hasConceptScore W3159508826C159654299 @default.
• W3159508826 hasConceptScore W3159508826C187212893 @default.
• W3159508826 hasConceptScore W3159508826C203014093 @default.
• W3159508826 hasConceptScore W3159508826C2522874641 @default.
• W3159508826 hasConceptScore W3159508826C2776572573 @default.
• W3159508826 hasConceptScore W3159508826C2777185649 @default.
• W3159508826 hasConceptScore W3159508826C2777483564 @default.
• W3159508826 hasConceptScore W3159508826C2777604421 @default.
• W3159508826 hasConceptScore W3159508826C2777704947 @default.
• W3159508826 hasConceptScore W3159508826C2777991916 @default.
• W3159508826 hasConceptScore W3159508826C2778720950 @default.
• W3159508826 hasConceptScore W3159508826C2779338263 @default.
• W3159508826 hasConceptScore W3159508826C2779651940 @default.
• W3159508826 hasConceptScore W3159508826C2780372218 @default.
• W3159508826 hasConceptScore W3159508826C2780636500 @default.
• W3159508826 hasConceptScore W3159508826C2780640218 @default.
• W3159508826 hasConceptScore W3159508826C2780653079 @default.
• W3159508826 hasConceptScore W3159508826C2780775167 @default.
• W3159508826 hasConceptScore W3159508826C2781137167 @default.
• W3159508826 hasConceptScore W3159508826C71924100 @default.
• W3159508826 hasConceptScore W3159508826C83455156 @default.
• W3159508826 hasConceptScore W3159508826C90924648 @default.
• W3159508826 hasFunder F4320309052 @default.
• W3159508826 hasLocation W31595088261 @default.

• next